Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UFT/leucovorin chemoradiotherapy with or without cetuximab after gemcitabine + capecitabine induction in locally advanced pancreatic cancer
2008-000517-30Phase 2Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cetuximab in pancreatic adenocarcinoma (PDAC), Anaplastic Pancreatic Carcinoma (APC) and pancreatic cancer (PC) (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: 1-year overall survival. Started Nov 2008; status: terminated.
02
Drugs
cetuximab
03
Conditions
pancreatic adenocarcinoma (PDAC)Anaplastic Pancreatic Carcinoma (APC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2008-000517-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000517-30.